Overview

hMG (Human Menopausal Gonadotropin) is a hormonal preparation extracted from the urine of post-menopausal women. It contains a combination of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) in approximately equal amounts (typically 75 IU of each per vial).

It has been a cornerstone of fertility medicine since its introduction in the 1960s and remains widely used for both female ovulation induction and male fertility optimization.

Key Characteristics

Origin: Extracted from post-menopausal urine
Classification: Gonadotropin preparation
Composition: FSH + LH (approximately 1:1 ratio)
Primary Use: Fertility treatments, hormonal optimization
FDA Status: Approved for fertility indications

Mechanism

hMG works by directly stimulating the gonads, bypassing the hypothalamic-pituitary axis.

Primary Mechanisms

1. FSH Actions

Follicle Stimulating Hormone acts on:

In Women:

Stimulates ovarian follicle development
Promotes estrogen production from granulosa cells
Induces aromatase enzyme activity
Essential for egg maturation

In Men:

Stimulates Sertoli cells in the testes
Promotes spermatogenesis
Supports sperm maturation
Maintains testicular function during HRT

2. LH Actions

Luteinizing Hormone provides:

In Women:

Triggers ovulation at mid-cycle (natural surge)
Promotes corpus luteum formation
Stimulates progesterone production
Essential for maintaining early pregnancy

In Men:

Stimulates Leydig cells
Promotes testosterone production
Supports testicular volume maintenance
Works synergistically with FSH

3. Synergistic Effect

The combination of FSH and LH in hMG provides a more "natural" stimulation pattern than FSH-only preparations, particularly important for:

LH-deficient patients
Male fertility optimization
Cases where pure FSH has failed

Research

Research Note: hMG has over 60 years of clinical use with extensive safety and efficacy data in fertility medicine.

Female Fertility

Ovulation Induction

Well-established uses include:

Polycystic Ovary Syndrome (PCOS) treatment
Hypothalamic amenorrhea
WHO Group II anovulation
Controlled ovarian hyperstimulation for IVF

2025 Developments

Recent protocols focus on:

Individualized dosing based on AMH and AFC
Reduced hyperstimulation risk with careful monitoring
Combination with GnRH antagonists for cycle control

Male Fertility

Spermatogenesis Induction

hMG is particularly valuable for:

Hypogonadotropic hypogonadism
Post-anabolic steroid fertility restoration
Testicular atrophy reversal
Maintaining fertility during TRT

Clinical Outcomes

Studies show:

50-80% success rate in achieving adequate sperm counts
Typically requires 6-12 months of treatment
Superior to FSH-only in many cases
Better testicular volume preservation

Comparison Studies

Research comparing hMG to recombinant FSH shows:

Similar pregnancy rates in IVF
hMG may provide better outcomes in poor responders
LH component beneficial in certain patient populations
Cost-effectiveness often favors hMG

Dosing

Disclaimer: hMG is a prescription medication that requires medical supervision. Dosing should be individualized based on response monitoring with ultrasound and blood tests.

Research Protocols

Administration Notes

For Fertility Protocols

Begin on day 2-3 of menstrual cycle (women)
Requires ultrasound monitoring for follicle development
Adjust dose based on estradiol levels and follicle count
Typically combined with hCG trigger for ovulation

For Male Use

Usually combined with hCG (1000-2000 IU 2-3x weekly)
hCG provides LH-like stimulation for testosterone
hMG provides additional FSH for spermatogenesis
Monitor sperm count every 2-3 months

Reconstitution

Comes as lyophilized powder with diluent
Mix gently - do not shake
Use immediately after reconstitution
Store unreconstituted vials refrigerated

Pharmacokinetics

Absorption

Subcutaneous: Peak levels in 12-24 hours
Intramuscular: Similar absorption profile
Bioavailability approximately 70%

Distribution

FSH half-life: 24-48 hours
LH half-life: 20-24 hours
Accumulation occurs with daily dosing

Metabolism

Primarily hepatic metabolism
Both hormones cleared by liver and kidneys

Elimination

FSH: Slower clearance, more stable levels
LH: Faster clearance, more pulsatile activity
Terminal half-life allows every-other-day dosing

Comparison: hMG vs Other Gonadotropins

Feature	hMG	Recombinant FSH	hCG
Contains FSH	Yes	Yes	No
Contains LH	Yes	No	LH-like activity
Origin	Urinary	Recombinant	Urinary/Recombinant
Primary Use	Fertility	Ovulation	Trigger/Testosterone
Cost	Moderate	Higher	Lower
LH-Deficient Patients	Preferred	May need LH added	Not sufficient

Synergy & Stacking

Common Combinations

hMG + hCG (Male Fertility)

The standard combination for male fertility:

hCG 1000-2000 IU 2-3x weekly (for testosterone)
hMG 75-150 IU 2-3x weekly (for spermatogenesis)
Duration: 6-12 months minimum
Monitor testosterone and sperm parameters

hMG + GnRH Antagonist (Female IVF)

For controlled ovarian stimulation:

hMG provides follicular stimulation
Antagonist prevents premature LH surge
Allows precise timing of egg retrieval

hMG + Clomiphene (Conservative Protocol)

For mild stimulation:

Clomiphene first, then low-dose hMG
Reduces medication costs
Lower risk of hyperstimulation

Safety

Known Side Effects

Common (Women)

Ovarian hyperstimulation syndrome (OHSS) - dose-related
Bloating and abdominal discomfort
Mood changes
Headache
Injection site reactions

Common (Men)

Gynecomastia (due to increased estrogen)
Acne
Injection site reactions
Testicular tenderness

Serious Risks

Multiple pregnancy (with ovulation induction)
Severe OHSS requiring hospitalization
Thromboembolic events (rare)
Ectopic pregnancy

Contraindications

Absolute Contraindications:

Primary ovarian/testicular failure
Uncontrolled thyroid or adrenal dysfunction
Sex hormone-dependent tumors
Pregnancy
Unexplained vaginal bleeding

Relative Contraindications:

High baseline estradiol
Large ovarian cysts
Severe obesity
Previous severe OHSS

Important: hMG treatment in women requires careful monitoring with ultrasound and blood tests to prevent ovarian hyperstimulation syndrome. Never self-administer without medical supervision.

Monitoring

For Women (Fertility Treatment)

During Stimulation:

Transvaginal ultrasound every 2-3 days
Serum estradiol levels
Follicle count and size measurement
Endometrial thickness

Safety Monitoring:

Watch for OHSS symptoms
Multiple follicle development
Ovarian enlargement

For Men

Baseline:

Semen analysis
Testosterone, FSH, LH levels
Testicular ultrasound

During Treatment:

Semen analysis every 2-3 months
Hormone levels periodically
Estradiol (watch for elevation)

Regulatory

Current Status

Region	Status
United States	FDA-approved (Menopur, Repronex)
European Union	EMA-approved
WADA	Not banned
Availability	Prescription only

Legal Considerations

Legally available by prescription worldwide
Covered by insurance for fertility indications
Off-label use for male optimization common
Requires medical supervision and monitoring

Clinical Outlook

hMG remains a valuable option in fertility medicine, particularly for:

Patients with LH deficiency
Male fertility optimization
Cost-conscious treatment approaches
Cases where recombinant FSH alone fails

References

[] Huirne JA, et al.. Contemporary pharmacological manipulation in assisted reproduction. Drugs ()

[] Matorras R, et al.. Recombinant FSH versus highly purified FSH in intrauterine insemination. Fertility and Sterility ()

[] Bouloux P, et al.. Induction of spermatogenesis by recombinant FSH in hypogonadotropic males. New England Journal of Medicine ()

[] Fertility Research Updates. Gonadotropin Protocols: hMG vs Recombinant Preparations. Reproductive Medicine Review ()

hMG